相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin
Aziz Zaanan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Colon Cancer, Version 2.2021
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines
A. Grothey et al.
ANNALS OF ONCOLOGY (2021)
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma
Lionel A. Kankeu Fonkoua et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Thierry Andre et al.
LANCET ONCOLOGY (2021)
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer
A. Guyot D'Asnieres De Salins et al.
ESMO OPEN (2021)
Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
Violaine Randrian et al.
CANCERS (2021)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study
David Tougeron et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
H. Yoon et al.
ANNALS OF ONCOLOGY (2020)
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer
Patricia Martin-Romano et al.
EUROPEAN JOURNAL OF CANCER (2020)
Treatment after progression in the era of immunotherapy
Salem Billan et al.
LANCET ONCOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Nivolumab (NIVO) plus low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
J. Taieb et al.
ANNALS OF ONCOLOGY (2019)
Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
Akinori Sasaki et al.
ESMO OPEN (2019)
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
Mari Tone et al.
LUNG CANCER MANAGEMENT (2019)
The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors
Laetitia Marisa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors
Laetitia Marisa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2017)
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency
R. Cohen et al.
EUROPEAN JOURNAL OF CANCER (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
分享论文
